PROPHASE LABS INC (PRPH)
US74345W1080 - Common Stock
Taking everything into account, PRPH scores 3 out of 10 in our fundamental rating. PRPH was compared to 194 industry peers in the Pharmaceuticals industry. PRPH may be in some trouble as it scores bad on both profitability and health. PRPH has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
PRPH had negative earnings in the past year.
PRPH had a negative operating cash flow in the past year.
In multiple years PRPH reported negative net income over the last 5 years.
In the past 5 years PRPH reported 4 times negative operating cash flow.
1.2 Ratios
PRPH's Return On Assets of -28.08% is in line compared to the rest of the industry. PRPH outperforms 57.29% of its industry peers.
PRPH has a Return On Equity of -59.69%. This is comparable to the rest of the industry: PRPH outperforms 50.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.08% | ||
| ROE | -59.69% | ||
| ROIC | N/A |
ROA(3y)3.3%
ROA(5y)-4.41%
ROE(3y)1.95%
ROE(5y)-8.33%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for PRPH so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PRPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
PRPH has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PRPH has more shares outstanding
Compared to 1 year ago, PRPH has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -0.89, we must say that PRPH is in the distress zone and has some risk of bankruptcy.
PRPH has a Altman-Z score (-0.89) which is in line with its industry peers.
A Debt/Equity ratio of 0.24 indicates that PRPH is not too dependend on debt financing.
PRPH's Debt to Equity ratio of 0.24 is in line compared to the rest of the industry. PRPH outperforms 41.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.89 |
ROIC/WACCN/A
WACC11.27%
2.3 Liquidity
PRPH has a Current Ratio of 1.58. This is a normal value and indicates that PRPH is financially healthy and should not expect problems in meeting its short term obligations.
PRPH has a Current ratio of 1.58. This is in the lower half of the industry: PRPH underperforms 73.96% of its industry peers.
PRPH has a Quick Ratio of 1.44. This is a normal value and indicates that PRPH is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.44, PRPH is doing worse than 71.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.58 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
The earnings per share for PRPH have decreased strongly by -426.09% in the last year.
The Revenue for PRPH has decreased by -77.11% in the past year. This is quite bad
The Revenue has been growing by 27.64% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-426.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-65%
Revenue 1Y (TTM)-77.11%
Revenue growth 3Y45.2%
Revenue growth 5Y27.64%
Sales Q2Q%-81.28%
3.2 Future
The Earnings Per Share is expected to grow by 58.10% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 63.73% on average over the next years. This is a very strong growth
EPS Next Y36.51%
EPS Next 2Y58.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year15.53%
Revenue Next 2Y63.73%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
PRPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 1.57, which indicates a rather cheap valuation of PRPH.
Based on the Price/Forward Earnings ratio, PRPH is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 23.79. PRPH is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 1.57 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PRPH's earnings are expected to grow with 58.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.1%
EPS Next 3YN/A
5. Dividend
5.1 Amount
PRPH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PROPHASE LABS INC
NASDAQ:PRPH (11/13/2024, 8:00:01 PM)
After market: 0.7455 -0.02 (-3.18%)0.77
+0.03 (+4.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap14.69M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 1.57 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.08% | ||
| ROE | -59.69% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.58 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-426.09%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y36.51%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-77.11%
Revenue growth 3Y45.2%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y